casopitant: Clinical Trials

12 trials of casopitant, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

11 completed, 1 terminated. 12 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 212Completed 11, Terminated 1

Follow casopitant: new trials by email Literature Review of casopitant trials Research Report on casopitant

Trials (filtered) newest first · largest first

All 12 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Evaluation of A Morning Dosing Of A New Medicine And Its Effects On Sleep At Bedtime In Subjects With Primary Insomnia
GW679769 - Sleep Initiation and Maintenance Disorders, Insomnia
Phase 2CompletedGlaxoSmithKline682006-05-012015-04-16
Effects Of GW679769 On Sleep Onset And Maintenance And Next Day Functioning In Subjects With Primary Insomnia
GW679769 - Sleep Initiation and Maintenance Disorders, Insomnia
Phase 2CompletedGlaxoSmithKline3422006-01-012015-04-15
An Exploratory Study Examining The Effects Of Taking GW679769 Once-Daily For 4 Days In Patients With Functional Dyspepsia
GW679769 oral tablets, Placebo - Nonulcer Dyspepsia
Phase 2CompletedGlaxoSmithKline132006-01-012017-02-08
Effects Of GW679769 On Sleep Onset And Maintenance,And Next Day Functioning In The Elderly And Non-elderly With Primary Insomnia
GW679769 - Sleep Initiation and Maintenance Disorders, Insomnia
Phase 2CompletedGlaxoSmithKline1222006-01-012015-04-16
Effects Of GW679769 On Bladder Nerve Function And Symptoms Of Overactive Bladder In Spinal Cord Injury Patients
GW679769 - Incontinence, Urinary and Urinary Bladder, Overactive, Overactive Bladder
Phase 2TerminatedGlaxoSmithKline12006-01-012015-04-17
A Study Of GW679769 Compared To Placebo In Women With Overactive Bladder
GW679769 oral tablets - Incontinence, Urinary and Urinary Bladder, Overactive, Overactive Bladder
Phase 2CompletedGlaxoSmithKline1602005-12-012017-01-20
Study Of The Effects Of A New Antidepressant Therapy In Patients With Major Depressive Disorder (MDD)
GW679769 - Depressive Disorder, Major
Phase 2CompletedGlaxoSmithKline3482005-06-012016-10-28
Post-Operative Nausea And Vomiting Study In Female Patients
GW679769 - Postoperative Nausea and Vomiting, Nausea and Vomiting, Postoperative
Phase 2CompletedGlaxoSmithKline4352005-02-012017-01-20
Study for The Prevention Of Nausea in Cancer Patients Receiving Highly Emetogenic Cisplatin Based Chemotherapy
Aprepitant, Ondansetron, GW679769 - Nausea and Vomiting, Chemotherapy-Induced
Phase 2CompletedGlaxoSmithKline4922005-02-012010-05-10
Study Of Prevention of Chemo-Induced Nausea and Vomiting Caused By Moderately Emetogenic Chemotherapy
GW679769, Dexamethasone, Ondansetron Hydrochloride - Nausea and Vomiting, Chemotherapy-Induced, Chemotherapy-Induced Nausea and Vomiting
Phase 2CompletedGlaxoSmithKline7222004-12-012015-04-16
Study Of GW679769 In Major Depressive Disorder
GW679769 - Depressive Disorder, Major, Major Depressive Disorder (MDD)
Phase 2CompletedGlaxoSmithKline3562004-10-012015-04-16
A Study to Evaluate the Effects of GW679769 on Sleep and Cognitive Function in Subjects With Primary Insomnia
GW679769, Placebo - Sleep Initiation and Maintenance Disorders
Phase 2CompletedGlaxoSmithKline482004-07-302017-08-08

Conditions studied

Sleep Initiation and Maintenance Disorders (4)  ·  Vomiting (3)  ·  Depressive Disorder, Major (2)  ·  Nausea (2)  ·  Urinary Bladder, Overactive (2)  ·  Depression (1)  ·  Mood Disorders (1)  ·  Postoperative Nausea and Vomiting (1)  ·  Spinal Cord Injuries (1)  ·  Urinary Incontinence, Urge (1)

Sponsors

GlaxoSmithKline (12)

Countries

United States (9)  ·  Canada (4)  ·  Argentina (3)  ·  Belgium (3)  ·  Chile (3)  ·  Germany (3)  ·  Hong Kong (3)  ·  Hungary (3)  ·  Philippines (3)  ·  Poland (3)  ·  Slovakia (3)  ·  Spain (3)  ·  Austria (2)  ·  Croatia (2)  ·  Czechia (2)

Results publications

PMID 19834961